Subscribe
formatoriginal-regeneron-1-
11 November 2021Big PharmaAlex Baldwin

PTAB grants IPR of Regeneron Eylea patents

The  US Patent Trial and Appeal Board will review the validity of two  Regeneron Pharmaceuticals patents related to its Eylea (aflibercept) medication.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Pressure-reducing eye drop patents in dispute
5 July 2022   Licensing partners aim to prevent the introduction of a proposed eye drop generic treatment before the expiration of four patents.
article
Regeneron convinces PTAB to review Novartis syringe patent
28 October 2021   The US Patent Trial and Appeal Board (PTAB) has granted a review of a Novartis syringe patent following a challenge from biotech giant Regeneron.
Big Pharma
Regeneron asks court to dismiss COVID-19 tech patent suit
24 August 2021   Regeneron wants a Manhattan district court to toss a lawsuit that claims it infringed on patents in the development and testing of COVID-19 treatments.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Americas
Pressure-reducing eye drop patents in dispute
5 July 2022   Licensing partners aim to prevent the introduction of a proposed eye drop generic treatment before the expiration of four patents.
article
Regeneron convinces PTAB to review Novartis syringe patent
28 October 2021   The US Patent Trial and Appeal Board (PTAB) has granted a review of a Novartis syringe patent following a challenge from biotech giant Regeneron.
Big Pharma
Regeneron asks court to dismiss COVID-19 tech patent suit
24 August 2021   Regeneron wants a Manhattan district court to toss a lawsuit that claims it infringed on patents in the development and testing of COVID-19 treatments.

More on this story

Americas
Pressure-reducing eye drop patents in dispute
5 July 2022   Licensing partners aim to prevent the introduction of a proposed eye drop generic treatment before the expiration of four patents.
article
Regeneron convinces PTAB to review Novartis syringe patent
28 October 2021   The US Patent Trial and Appeal Board (PTAB) has granted a review of a Novartis syringe patent following a challenge from biotech giant Regeneron.
Big Pharma
Regeneron asks court to dismiss COVID-19 tech patent suit
24 August 2021   Regeneron wants a Manhattan district court to toss a lawsuit that claims it infringed on patents in the development and testing of COVID-19 treatments.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB